Published in Expert Opin Biol Ther on August 01, 2008
Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler Thromb Vasc Biol (2011) 0.91
Maternal malaria induces a procoagulant and antifibrinolytic state that is embryotoxic but responsive to anticoagulant therapy. PLoS One (2012) 0.91
Defibrotide: a Swiss Army knife intervention in the battle against cerebral malaria. Arterioscler Thromb Vasc Biol (2012) 0.76
A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 7.87
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature (1998) 4.03
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science (1985) 2.33
CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. J Exp Med (1997) 2.24
Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia (2002) 2.23
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant (2007) 2.03
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet (1997) 1.94
A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A (1984) 1.79
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst (1983) 1.72
Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord (2001) 1.70
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med (1990) 1.52
The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood (1989) 1.51
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer (2009) 1.48
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells. Proc Natl Acad Sci U S A (1983) 1.48
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Chlamydia trachomatis infection in children with wheezing simulating asthma. Lancet (1992) 1.42
An international comparison of knowledge levels of medical students: the Maastricht Progress Test. Med Educ (1996) 1.42
Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: Data from the GH Registry. J Endocrinol Invest (2006) 1.39
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Haematologica (1999) 1.39
Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology (2000) 1.38
Transmission of prions. Proc Natl Acad Sci U S A (2002) 1.36
Anion conductance behavior of the glutamate uptake carrier in salamander retinal glial cells. J Neurosci (1996) 1.34
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol (2008) 1.34
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood (1992) 1.33
Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene (1997) 1.31
Spatially segregated control of Ca2+ release in developing skeletal muscle of mice. J Physiol (1999) 1.31
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
The inherent cytotoxicity of melanin precursors: a revision. Biochim Biophys Acta (1994) 1.29
Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells. J Biol Chem (1997) 1.27
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol (1999) 1.26
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem (1996) 1.21
Cloning and structural characterization of a human non-erythroid band 3-like protein. EMBO J (1986) 1.21
In situ activation of the type 2 ryanodine receptor in pancreatic beta cells requires cAMP-dependent phosphorylation. Proc Natl Acad Sci U S A (1998) 1.21
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia (2011) 1.17
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia (1994) 1.16
Sleep abnormalities in type 2 diabetes may be associated with glycemic control. Acta Diabetol (2008) 1.16
Harrington instrumentation and arthrodesis for idiopathic scoliosis. A twenty-one-year follow-up. J Bone Joint Surg Am (1990) 1.15
Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer (1993) 1.15
The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia (2012) 1.14
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia (2010) 1.12
The role of glutamate transporters in glutamate homeostasis in the brain. J Exp Biol (1997) 1.12
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol (1984) 1.12
A comparison of the alcohol-attributable mortality in four European countries. Eur J Epidemiol (2003) 1.11
First evidence of peste des petits ruminants (PPR) virus circulation in Algeria (Sahrawi territories): outbreak investigation and virus lineage identification. Transbound Emerg Dis (2011) 1.11
B lymphocyte-restricted expression of prion protein does not enable prion replication in prion protein knockout mice. Proc Natl Acad Sci U S A (2001) 1.10
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica (2001) 1.10
IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol (2001) 1.10
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia (2005) 1.10
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia (2011) 1.09
Effect of metal ions on the rearrangement of dopachrome. Biochim Biophys Acta (1987) 1.08
Transmission of prions. J Infect Dis (2002) 1.08
Lineage infidelity of a human myelogenous leukemia cell line. Blood (1984) 1.07
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia (2012) 1.07
Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor T cells. Proc Natl Acad Sci U S A (1981) 1.06
Reliability of death certifications for different types of cancer. An autopsy survey. Pathol Res Pract (1986) 1.06
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia (2010) 1.06
Characterization and mapping of the 12 kDa FK506-binding protein (FKBP12)-binding site on different isoforms of the ryanodine receptor and of the inositol 1,4,5-trisphosphate receptor. Biochem J (2001) 1.05
[Bladder metastasis of malignant melanoma: a case report and review of literature]. Prog Urol (2008) 1.05
Gallstone ileus: One-stage surgery in an elderly patient: One-stage surgery in gallstone ileus. Int J Surg Case Rep (2013) 1.05
Physiological and pathological operation of glutamate transporters. Prog Brain Res (1998) 1.04
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol (2005) 1.03
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol (2011) 1.02
Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project. AIDS Res Hum Retroviruses (2010) 1.02
Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. Cancer Treat Rev (1988) 1.02
Altered expression of growth-regulated protooncogenes in human malignant plasma cells. Cancer Res (1989) 1.02
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer (2008) 1.01
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia (2009) 1.01
Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. Eur J Neurosci (1997) 1.00
Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res (2000) 1.00
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood (1999) 0.99
Sequence comparison of human and murine erythrocyte alpha-spectrin cDNA. Gene (1985) 0.99